Do GNOM and IDNA hold the same stocks?

By their latest filings, 25% of their books are the same securities at the same weight. Overlap is the sum of the smaller weight of every security they share.

Which is more different from the S&P 500, GNOM or IDNA?

GNOM has 21% of its weight in S&P 500 names and IDNA has 27%, so IDNA differs more from the index.

Which is cheaper, GNOM or IDNA?

GNOM charges 0.50% a year and IDNA charges 0.47%, so IDNA is cheaper. Fees come from each fund's prospectus.

Data as of Nov 4, 2026.

Thematic ETFs

GNOM vs IDNA: Holdings Overlap & Returns

Share on X Download as PDF

Over the year to Nov 4, 2026, GNOM returned +66.6% to IDNA's +81.1%; 25% of their weight is in the same names.

askIQ about this page

askIQ about GNOM and IDNA

Net assets: $104m on Oct 12, 2026 for Global X Genomics & Biotechnology ETF, and $340m on Nov 3, 2026 for iShares Genomics Immunology and Healthcare ETF.

GNOM on its own →IDNA on its own →

At a glance

21.0%

GNOM in the S&P 500

27.4%

IDNA in the S&P 500

+66.6%

GNOM total return, 1 year

+81.1%

IDNA total return, 1 year

GNOM · 1 year to Nov 4, 2026 79% of its weight is outside the S&P 500

21% of GNOM's weight is in S&P 500 companies and 79% is outside the index. Holdings as of Aug 31, 2026.

IDNA · 1 year to Nov 4, 2026 73% of its weight is outside the S&P 500

27% of IDNA's weight is in S&P 500 companies and 73% is outside the index. Holdings as of Nov 3, 2026.

Pair scorecard

IDNA costs 0.03 points a year less; their one-year returns differ by 14.5 points; IDNA is 3.0 times larger.

GNOM vs IDNA: Holdings Overlap & Returns
Measure	GNOM	IDNA
Return
Measure	GNOM	IDNA
Total return, 1 year	+66.6%	+81.1%
Drawdown
Measure	GNOM	IDNA
Below its all-time high	36.2%, high on Feb 8, 2021	16.5%, high on Sep 2, 2021
Benchmark
Measure	GNOM	IDNA
What it tracks	Genomics and gene editing	Genomics and gene editing
Cost and size
Measure	GNOM	IDNA
Expense ratio	0.50%	0.47%
Net assets, as of Oct 12, 2026	$104m	$315m
Holdings
Measure	GNOM	IDNA
Holdings in common	25%

Method

Risk and return

Jun 21, 2019 to Oct 30, 2026 · 384 weekly returns

GNOM IDNA

Return

Total return edge IDNA +18.2% +69.5%

Annualized edge IDNA +2.3% +7.4%

Price return edge IDNA +16.2% +59.6%

Risk

Volatility edge IDNA (slight) 33.1% 30.1%

Max drawdown edge IDNA (slight) −73.5% −68.1%

Risk-adjusted

Sharpe edge IDNA 0.15 0.29

Sortino edge IDNA 0.22 0.44

Calmar edge IDNA 0.03 0.11

Reading

From Jun 2019 to Oct 2026, IDNA returned more: +69.5% to +18.2%. IDNA swung slightly less: 30.1% to 33.1%. IDNA fell slightly less at its worst: −68.1% to −73.5%.

Full scorecard

9 measures, with how each is measured Open ↓

Risk and return: GNOM vs IDNA: Holdings Overlap & Returns
Measure	GNOM	IDNA	Edge	How it is measured
Return
Total return	+18.2%	+69.5%	IDNA	Price change plus distributions, reinvested.
Annualized	+2.3%	+7.4%	IDNA	Total return as a yearly rate.
Price return	+16.2%	+59.6%	IDNA	Price change alone, distributions left out.
Risk
Volatility	33.1%	30.1%	IDNA (slight)	Spread of weekly returns, annualized. Lower is steadier.
Downside deviation	22.5%	20.2%	IDNA	Like volatility, counting only weeks below the Treasury bill rate.
Max drawdown	−73.5%	−68.1%	IDNA (slight)	Deepest fall from a high to the low after it.
Risk-adjusted
Sharpe	0.15	0.29	IDNA	Return above Treasury bills per unit of volatility.
Sortino	0.22	0.44	IDNA	Return above Treasury bills per unit of downside deviation.
Calmar	0.03	0.11	IDNA	Annualized return divided by the max drawdown.

Computed by ETFIQ from Tiingo daily prices and ETFIQ's distribution records, 384 weekly returns. Cash rate: the 13-week Treasury bill.

What they share

25%

By the books each fund has filed, GNOM and IDNA hold 25% of their money in the same securities at the same weight. Holdings dated Aug 31, 2026 and Nov 3, 2026.

50%

0 half 100%

half

25% in common

Positions both hold · largest shared weight first GNOM IDNA

MODERNA, INC. 7.50% 13.33%

Twist Bioscience Corporation 6.34% 5.61%

VERTEX PHARMACEUTICALS INCORPORATED 3.70% 3.29%

BioNTech SE 2.78% 2.73%

CARIS LIFE SCIENCES, INC. 2.38% 3.50%

CRISPR Therapeutics AG 3.00% 1.24%

Vir Biotechnology, Inc. 0.98% 1.30%

Personalis, Inc. 0.89% 0.85%

INTELLIA THERAPEUTICS, INC. 1.11% 0.44%

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 0.28% 0.61%

Prime Medicine, Inc. 0.26% 0.12%

Only in one fund ↓

Only in GNOM

10x Genomics, Inc. 5.48%

GUARDANT HEALTH, INC. 5.28%

ILLUMINA, INC. 4.87%

NATERA, INC. 4.61%

Genscript Biotech Corp 3.81%

BIO-TECHNE CORPORATION 3.67%

BIOMARIN PHARMACEUTICAL INC. 3.58%

ARROWHEAD PHARMACEUTICALS, INC. 3.31%

Only in IDNA

GENMAB 6.26%

REGENERON PHARMACEUTICALS 4.24%

BAYER AG 3.85%

EXELIXIS INC 3.80%

TAKEDA PHARMACEUTICAL 3.77%

REVOLUTION MEDICINES 3.60%

MERCK & CO INC 3.32%

ROCHE PS PAR AG 3.20%

Check overlap with more funds →

Window by window

Window by window: GNOM vs IDNA: Holdings Overlap & Returns
	Total return
Window	GNOM	IDNA
3 months	+24.5%	+32.4%
6 months	+49.4%	+45.6%
1 year	+66.6%	+81.1%
3 years	+81.6%	+134.8%
Since launchNot the same days: GNOM Apr 2019 · IDNA Jun 2019	+16.0%	+88.1%

Open this comparison in the app →

Side by side

GNOM Global X Genomics & Biotechnology ETF · Holds 50 stocks in genomics and gene editing, 21% of its weight in S&P 500 companies IDNA iShares Genomics Immunology and Healthcare ETF · Holds 52 stocks in genomics and gene editing, 27% of its weight in S&P 500 companies

Issuer Global X iShares

Theme Genomics and gene editing Genomics and gene editing

In the S&P 500 21.0% 27.4%

Active share vs the S&P 500 97.6% 99.1%

In the Nasdaq-100 5.3% 7.5%

Holdings 50 52

Top ten, share of the fund 48.8% 51.3%

Expense ratio 0.50% 0.47%

Fee for the differing part 0.51% 0.47%

Total return, 1 year +66.6% +81.1%

vs its benchmark not measured not measured

Below its high −36.2% −16.5%

Net assets, GNOM as of Oct 12, 2026 and IDNA as of Nov 3, 2026 $104m $340m

As of Nov 4, 2026. Source: ETFIQ.

25% of the two portfolios are the same securities at the same weight.

Client brief:

The two-page PDF for this pair is coming. Save the comparison to follow its changes. Free. It needs an email sign-in, once.

Your saved page · Privacy.

Alert

About each fund

GNOM

By weight, 21% of GNOM's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 98%. The top ten holdings are 49% of the fund across 50 positions, as filed for Aug 31, 2026. Over the year to Nov 4, 2026 the fund returned +66.6% with distributions reinvested. It sits 36.2% below its all-time high of Feb 8, 2021.

IDNA

By weight, 27% of IDNA's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 99%. The top ten holdings are 51% of the fund across 52 positions, as published by its issuer for Nov 3, 2026. Over the year to Nov 4, 2026 the fund returned +81.1% with distributions reinvested. It sits 16.5% below its all-time high of Sep 2, 2021.

Questions people ask

Do GNOM and IDNA hold the same stocks?: By their latest filings, 25% of their books are the same securities at the same weight. Overlap is the sum of the smaller weight of every security they share.
Which is more different from the S&P 500, GNOM or IDNA?: GNOM has 21% of its weight in S&P 500 names and IDNA has 27%, so IDNA differs more from the index.
Which is cheaper, GNOM or IDNA?: GNOM charges 0.50% a year and IDNA charges 0.47%, so IDNA is cheaper. Fees come from each fund's prospectus.

Other comparisons

GNOM vs ARKG GNOM vs GNMX GNOM vs IBBQ GNOM vs PBE IDNA vs ARKG IDNA vs GNMX IDNA vs BBH IDNA vs BBP

Where to next

All thematic ETFs ranked by the S&P 500 Difference Score →How the scores are computed →GNOM on its own →IDNA on its own →GNOM dividend history →GNOM holdings →IDNA dividend history →IDNA holdings →Method →Standards and sources →

Sources and dates

GNOM filings on SEC EDGAR ↗

GNOM prospectus with the expense ratio (SEC) ↗

Global X page for GNOM ↗

IDNA filings on SEC EDGAR ↗

IDNA prospectus with the expense ratio (SEC) ↗

iShares page for IDNA ↗

Links are sources, not endorsements. A comparison is not a recommendation.

How this is computed

Overlap adds up the smaller of the two weights for each security both funds hold.

Every number is an ETFIQ calculation with distributions reinvested.

Cite this pageCitation, APA and Markdown

ETFIQ, GNOM against IDNA, data as of Nov 4, 2026. https://etfiq.com/compare/themes/gnom-vs-idna

Open data →

Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms.